Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Two-part, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR206 in Healthy Volunteers

Trial Profile

A Phase 1, Two-part, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR206 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs SPR-206 (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Urinary tract infections
  • Focus Adverse reactions; First in man
  • Sponsors Spero Therapeutics
  • Most Recent Events

    • 07 Jan 2019 According to a Spero Therapeutics media release, top-line data from the study is expected in the second half of 2019.
    • 31 Dec 2018 Status changed from planning to recruiting.
    • 08 Nov 2018 According to a Spero Therapeutics media release, the company is planning to start this study around year-end 2018 .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top